Technical Analysis for SKYE - Skye Bioscience Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 5.71% | |
| Inside Day | Range Contraction | 5.71% | |
| Wide Bands | Range Expansion | 5.71% | |
| Oversold Stochastic | Weakness | 5.71% | |
| Stochastic Buy Signal | Bullish | -0.45% | |
| Doji - Bullish? | Reversal | -0.45% | |
| Lower Bollinger Band Walk | Weakness | -0.45% | |
| Wide Bands | Range Expansion | -0.45% | |
| Lower Bollinger Band Touch | Weakness | -0.45% | |
| Oversold Stochastic | Weakness | -0.45% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 5% | about 2 hours ago |
| Up 3% | about 2 hours ago |
| 2x Volume Pace | about 2 hours ago |
| 1.5x Volume Pace | about 2 hours ago |
| Down 3% | about 3 hours ago |
Get this analysis on your stocks daily!
Skye Bioscience Inc Description
Skye Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is based in San Diego, California
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medical Specialties Clinical Medicine Biopharmaceutical Diabetes Ophthalmology Glaucoma Macular Degeneration Diabetic Retinopathy Retinopathy Blindness Uveitis Staphylococcus Aureus Eye Disease Eye Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.0595 |
| 52 Week Low | 0.0105 |
| Average Volume | 1,898,574 |
| 200-Day Moving Average | 0.0273 |
| 50-Day Moving Average | 0.0291 |
| 20-Day Moving Average | 0.0265 |
| 10-Day Moving Average | 0.0240 |
| Average True Range | 0.0045 |
| RSI | 35.06 |
| ADX | 22.7 |
| +DI | 13.3333 |
| -DI | 21.9048 |
| Chandelier Exit (Long, 3 ATRs) | 0.0242 |
| Chandelier Exit (Short, 3 ATRs) | 0.0335 |
| Upper Bollinger Bands | 0.0332 |
| Lower Bollinger Band | 0.0198 |
| Percent B (%b) | 0.09 |
| BandWidth | 50.5660 |
| MACD Line | -0.0025 |
| MACD Signal Line | -0.0019 |
| MACD Histogram | -0.0007 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.0246 | ||||
| Resistance 3 (R3) | 0.0247 | 0.0236 | 0.0240 | ||
| Resistance 2 (R2) | 0.0236 | 0.0227 | 0.0236 | 0.0238 | |
| Resistance 1 (R1) | 0.0223 | 0.0221 | 0.0218 | 0.0222 | 0.0236 |
| Pivot Point | 0.0212 | 0.0212 | 0.0209 | 0.0212 | 0.0212 |
| Support 1 (S1) | 0.0199 | 0.0203 | 0.0194 | 0.0198 | 0.0184 |
| Support 2 (S2) | 0.0188 | 0.0197 | 0.0188 | 0.0182 | |
| Support 3 (S3) | 0.0175 | 0.0188 | 0.0180 | ||
| Support 4 (S4) | 0.0174 |
